Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support
Gossamer BioGossamer Bio(US:GOSS) Businesswire·2026-05-18 19:05

公司动态 - 生物制药公司Gossamer Bio宣布启动一项交换要约，旨在将其2027年到期的5.00%可转换优先票据全部交换为新的票据[1] - 公司专注于开发及商业化药物seralutinib，用于治疗肺动脉高压以及间质性肺病相关肺动脉高压[1]

Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support - Reportify